Triple-negative breast cancer (TNBC), which lacks the expression of estrogen receptor (ER) and progesterone receptor (PR) and has low or no expression of human epidermal growth factor receptor 2 (HER2), accounts for 15–20% of all breast cancers diagnosed worldwide [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.